This week's roundup of Houston innovators includes Kaitlyn Allen of MendIt, Miguel Calatayud of iwi, and Tatiana Fofanova of Koda Health. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from sustainability to health tech — recently making headlines in Houston innovation.

Kaitlyn Allen, founder and chief strategy officer of MendIt

MendIt seeks to reduce textile waste by providing an easy-to-use app to make menders and customizers more accessible. Photo courtesy of MendIt

Kaitlyn Allen thought she had a great idea for a company — something that can help people repair clothing conveniently. And all of the pieces of the strategy already existed. There are plenty of seamstressing businesses around town, but not an easy way to navigate them. “

There’s a disconnect. There’s a market of people who potentially want to mend their clothes, but there’s no easy way of finding or accessing that service,” she says. “With this next generation, you need to meet them where they are.”

And where they are, Allen says, is on their phones.

MendIt is completing a pilot program with one mender — Connect Community in Gulfton area — in partnership with St. Luke's Gethsemane on Bellaire in Sharpstown. She also hopes to tap into a local artist who can help with customization — like embroidery, for instance. Click here to read more.

Miguel Calatayud, CEO of iwi

Miguel Calatayud, CEO of iwi, joins the Houston Innovators Podcast to discuss his sustainable business of farming algae for nutritional products. Photo courtesy of iwi

Miguel Calatayud feels like he has the perfect storm of a product. Not only does his company iwi's nutritional supplement have a sustainability focus, it's also just a very competitive product in the marketplace. The company has created a sustainable suite of products from innovative algae farming in the deserts of Texas and New Mexico. These football field-sized farms operate on desert land using just salt water and sand and produce algae sustainably — all while absorbing CO2.

"We've been growing significantly for one main reason," Calatayud says. "It works."

Calatayud shares more about the impact he's making and why Houston is the ideal market for him to do it in on the Houston Innovators podcast. Click here to read more.

Tatiana Fofanova, co-founder and CEO of Koda Health

Tatiana Fofanova, co-founder and CEO of Koda, closed recent funding for the digital health startup. Image via LinkedIn

Tatiana Fofanova, Koda co-founder and CEO, has something to celebrate. The Houston-based startup announced this month that it raised $3.5 million in its latest seed round. The funding will be used to help the digital advanced care planning company double the size of its team in the next six months.

"Koda Health helps vulnerable people navigate and communicate difficult decisions about their health care journey. So, when hiring, we look for empathetic people who are phenomenal communicators," Tatiana Fofanova, Koda co-founder and CEO, says in a statement.

The Koda team will also use the funds to expand its operations to all 50 states. According to the statement, the team plans to focus on low-resource communities and operating in different languages. Click here to read more.

Miguel Calatayud, CEO of iwi, joins the Houston Innovators Podcast to discuss his sustainable business of farming algae for nutritional products. Photo courtesy of iwi

How this Houston innovator plans to make a sustainable impact — one algae farm at a time

Houston innovators podcast episode 120

If there's one thing Miguel Calatayud is passionate about it's conscious capitalism — and specifically that his company, iwi, a Houston-based food and nutritional supplement company, is striking the perfect balance between impact and profit.

The company has created a sustainable suite of products from innovative algae farming in the deserts of Texas and New Mexico. These football field-sized farms operate on desert land using just salt water and sand and produce algae sustainably — all while absorbing CO2. Calatayud says the farms even area able to reuse 98 percent of the water involved in the process.

"In the past, you had to choose between making an impact and making a profit," Calatayud says on this week's episode of the Houston Innovators Podcast. "In our case, the way we built the company and the business model we put together, it's actually the opposite. The bigger the impact we make, the bigger the business we're creating."

With all this sustainability to boast about, Calatayud says it's not even the best part. Iwi's products, which include Omega-3 supplements, multivitamins, and even a forthcoming protein — all made from the farmed algae, are also very competitive products in the market.

"We've been growing significantly for one main reason," Calatayud says." It works."

"That's what's really driving the growth in the company because once a customer starts taking iwi, they don't go back to whatever they were taking before," Calatayud continues on the show.

Calatayud says iwi is ready to expand more internationally. The company recently closed an $8 million deal — $5.5 million in senior secured term debt and a $2.5 million direct equity investment — with GP Capital Partners, an investor and strategic partner for the company. The influx of funding will help iwi accelerate sales of its existing products and ramp up development, marketing, and growth of new protein-based product, according to the release. Iwi will also enter new international markets.

"What we are going to do with [GP] and other investors that we have is to take this brand to the next level," Calatayud says. "Last year, we grew 91 percent. This year, we are planning to grow around 200 percent."

Calatayud says the pond systems iwi operates are replicable, and as the company grows he could see building these types of algae farms across the world and even in the Middle East, creating jobs and opportunities globally.

Calatayud shares more about the impact he's making and why Houston is the ideal market for him to do it in on the podcast. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

European spacecraft developer expands to Houston with U.S. business, new lab

houston hq

European aerospace manufacturer The Exploration Company has established its first U.S. entity and named Space City as its headquarters.

The company announced earlier this month that it has launched TEC Federal to support U.S. government customers and agencies, and to scale The Exploration Company's engineering operations in the country.

Mark Kirasich serves as president of TEC Federal. Kirasich most recently served as the senior director of human spaceflight at Blue Origin after a nearly 40-year career at NASA.

The Exploration Company is developing the reusable Nyx space vehicle. Nyx is designed to take off from any heavy launcher in the world. It will then dock at space stations, retrieve up to 3,000 kilograms of cargo, splash down and return the cargo to Earth. The company aims to make Nyx fully reusable for up to 10 missions, making it a more affordable and sustainable option for aerospace missions.

The Exploration Company completed a successful drop test of the spacecraft in May in the Mojave Desert. The company says Nyx is slated to perform its first flight demonstration in 2028.

In addition to launching the Houston business, The Exploration Company also opened its new Rapid Innovation Lab near Houston's NASA Johnson Space Center on Space Park Drive.

The Exploration Company opened its Rapid Innovation Lab earlier this month. Photo via LinkedIn

The Rapid Innovation Lab features a full-scale mockup of the future Nyx crew capsule as well as ongoing development and testing of the Nyx cargo capsule, according to the company.

The Exploration Company says the new lab will allow its engineers, designers, and operators to prototype and test crew interfaces. It will also support partnerships with NASA personnel and astronauts.

“Houston gives us direct access to the people and expertise that have built and operated human spaceflight systems for decades. We’re excited to invest and expand around that— engineers, operators, and astronauts working together and moving quickly towards building a crew capsule.” Hélène Huby, founder and CEO of The Exploration Company, said in a blog post.

According to The Houston Chronicle, The Exploration Company has about 30 employees in the Houston area.

The company was founded in 2021 by Huby, a French rocket scientist, and has raised more than $350 million in venture capital. It operates out of Germany, France, Luxembourg, Spain and Italy, with offices in the U.S. and the United Arab Emirates. It is also developing a reusable, high-thrust rocket engine known as Storm.

UH lands $4M NIH grant to study early signs of autoimmune disease

NIH funding

The University of Houston recently received a $4 million National Institutes of Health grant to support a 10-year longitudinal study to identify the earliest biological markers of autoimmune disease.

Led by Chandra Mohan, the Hugh Roy and Lillie Cranz Cullen Endowed Professor of Biomedical Engineering, the study aims to examine what causes Systemic Autoimmune Rheumatic Diseases (SARDs) and to identify targets for future treatments. The study will be carried out in collaboration with Dr. Karen Costenbader at Harvard Medical School, Boston.

SARDs include conditions like rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome and systemic sclerosis—all are considered chronic diseases currently without a cure. Autoimmune diseases affect over 30 million people globally, according to UH.

SARDs occur when the body’s immune system attacks healthy, non-threatening tissues and organs. According to UH, in these diseases, the body often attacks nuclear antigens, creating anti-nuclear autoantibodies, which can be early detection signs for SARDs in more than 50 percent of patients, Mohan says.

Researchers will study blood samples and environmental exposure over the 10 years to better understand anti-nuclear autoantibodies.

“Collectively, these studies will help identify the genetic, environmental and cellular factors that are operative at the two steps of SARD development, namely the emergence of anti-nuclear autoantibodies and disease onset,” Mohan said in a news release. “ More importantly, these studies will highlight functional molecular pathways and mechanisms that may be operative at each step."

Mohan predicts that looking at SARDs’ shared characteristics, rather than each disease individually, could help identify more treatment methods.

“Individual SARDs have been examined in silos without an attempt to discern shared underlying features at the molecular level,” he added in the release. “Current understanding of the initial (and likely shared) origins of SARDs is only rudimentary but urgently needed to develop means for prevention and treatment.”

Earlier this year, UH also received an $11 million NIH grant to conduct a first-of-its-kind study of early language development in children ages 18 to 24 months. Read more here.